In prostate cancer studies have focused the UGT2B15(D85Y) and the UGT2B17 gene deletion variants, although a correlation between variations in the gene copy number and serum steroids was also reported (55, 56). This evidence concerns the gene UGT2B15 and prostate carcinoma.